TABLEĀ 1

Microbiological and demographic characteristics of the patients enrolled in the study

Lab no.Diagnosis yearExclusion reasonSexAge yearsRegion of isolationMDR/XDR-TBSTRINHRMPEMBPZAAMICAPETIMOXOFLLINKANCICPASCluster no.
S1992282014M42LTVXDRRRRRRRRRRRSSSS
2014No culture isolationM43LTVXDRRRRRRRRRRRSSSS
2014Only LPAM47LTVMDRNARRNANANANANANANANANANANA
TB254292014M41LTVMDRRRRRRSSRSSSSSS6
P15952014M37LTVMDRRRRSRSSRSSSSSS1
P12792014F31LTVMDRRRRRRSSRSSSRSS
S2077972014M53LTVMDRRRRSRSSRSSSSSS2
P14282014M48LTVMDRRRRSRSSRSSSSSS1
P13782014M50LTVXDRRRRRRSSRRRSRSS3
P1632014M53LTVXDRRRRRRRSRRRSRSS3
TB248182014F32LTVMDRRRRRSSSSSSSSSS7
P2912014M28LTVMDRRRRRSSSSSSSSSS
TB252742014M37LTVXDRRRRRRSSRSRSRRS
S2118912014M36LTVMDRRRRRSSSRSSSSSS7
P15992014M43LTVMDRRRRRSSSSSSSSSS6
P1872014M58LTVMDRRRRRRSSRSSSSSS2
P882014M63NorthMDRRRRSSSSSSSSSSS4
P4232014F75NorthMDRRRRSSSSSSSSSSS4
P2922014F41NorthMDRRRRSSSSSSSSSSS4
P15362014M23NorthMDRRRRSSSSSSSSSSS4
P7292014M47NorthMDRRRRSSSSSSSSSSS
P3562014M42NorthMDRSRRSSSSSSSSSSS
P922014M59CentreMDRRRRSSSSRSSSSSS2
P3402014M48CentreXDRRRRRSRSRSRSRSS3
2015Only LPAM31LTVMDRNARRNANANANANANANANANANANA
P26242015M28LTVMDRRRRRSSSRSSSSSS7
P19282015M61LTVMDRRRRRRSSRSSSSSS1
P12292015M39LTVXDRRRRRRRRRRRSRSS1
P18762015M55LTVXDRRRRRRRSRRRSRSS3
P19262015M52LTVXDRRRRRRRRRRRSRSS1
P28292015M44LTVMDRSRRSSSSRSSSSSS1
P21842015M75LTVMDRRRRRRRRRSSSRSS1
P19942015M41LTVMDRRRRSRSSRSSSSSS2
P20582015M57LTVMDRRRRSRSSRSSSSSS
TB247372015M44LTVXDRRRRRRRRSRRSRSR
P15852015F42LTVMDRRRRRSSSRSSSSSS3
P23542015F27LTVMDRRRRRRRRSSSSRSS
P24712015M34LTVMDRRRRRSSSRSSSSSS3
2015Only LPAF32LTVMDRNARRNANANANANANANANANANANA
P8842015M61LTVMDRRRRSRSSRSSSSSS2
P25792015M35LTVMDRRRRRRSSRSSSSSS
P24522015M57NorthMDRRRRSSSSRSSSSSS3
P9822015M37NorthMDRRRRRRSSSSSSSSS
P18802015M58NorthMDRRRRSSSSSSSSRSS
P23532015M21Island of MadeiraMDRSRRRSSSRSSSSSS5
P272015M44AlgarveMDRSRRSSSSRSSSSSS
2015Only LPAM39AlentejoMDRNARRNANANANANANANANANANANA
S3081442016M41LTVXDRRRRRRRSRRRSRSS3
S3099682016F41NorthMDRRRRSSSSSSSSSSS4
S3103682016M42NorthXDRRRRRRRSRRRSRSS3
S3122052016F63LTVMDRSRRSRRRRSSSRSS1
S3143712016M15LTVMDRRRRRSSSRSSSSSS6
S3241342016M61CentreMDRRRRRRSSSSSSRSS
2016No culture isolationF45LTVMDRRRRRRNANANANANANANANANA
S3265512016M40LTVMDRRRRRRSSSSSSSSS
S3278892016F22LTVXDRRRRRRRSRRRSRSS3
S3208572016M43LTVMDRRRRRRSSSSSSSSS
S3165692016M54NorthMDRRRRSSRRSSSSRSS
S3267822016M62NorthMDRRRRSSSSRSSSSSS3
S3402482016M20LTVMDRRRRSRSSRSSSSSS2
TB313932016F40LTVMDRRRRSSSSSSSSSSS
S3328462016M70CentreMDRRRRSRSSSSSSSSS
S3474012016F20LTVMDRRRRRSSSRSSSSSS
ACC2016F40LTVMDRRRRSRSSRSSSSSS2
S3336052016M62NorthMDRRRRSSSSRSSSSSS3
S3483872016MUNKCentreMDRSRRSSSSSSSSSSS
S3521392017F22CentreMDRRRRRRSSSSSSSSS6
S3750012017F22CentreMDRSRRRSSSRSSSSSS5
S3746862017F34LTVMDRSRRRRSSRSSSSSS
S3812772017M30NorthMDRRRRRSSSSSSSSSS
TB334702017M52LTVMDRSRRRRSSRSSSSSS1
S3898652017F59NorthMDRRRRRRSSSSSSSSS
S3876832017M56LTVXDRRRRRRRSRRRSRSS3
S3990452017F41NorthMDRRRRSSSSRRRSSSS
S3963972017M51LTVXDRRRRRRRRRSSSRSS1
S3999862017M58LTVMDRRRRRSSSRRRSSSS3
TB341922017M62LTVMDRRRRSSSSRSSSSSS2
2017Only LPAM54NorthMDRNARRNANANANANANANANANANANA

MDR: multidrug-resistant; XDR: extensively drug-resistant; TB: tuberculosis; STR: streptomycin; INH: isoniazid; RMP: rifampicin; EMB: ethambutol; PZA: pyrazinamide; AMI: amikacin; CAP: capreomycin; ETI: ethionamide; MOX: moxifloxacin; OFL: ofloxacin; LIN: linezolid; KAN: kanamycin; CIC: cycloserine; PAS: para-aminosalicylic acid; M: male; F: female; LTV: Lisbon and Tagus Valley; R: resistant; S: sensitive; NA: not available; LPA: line-probe assay; UNK: unknown.